Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million)Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor event with simultaneous conference call and webcast at 10:0 ...